Literature DB >> 9114134

Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans.

F Laguna1, J L Rodríguez-Tudela, J V Martínez-Súarez, R Polo, E Valencia, T M Díaz-Guerra, F Dronda, F Pulido.   

Abstract

We evaluated 119 episodes of oropharyngeal candidiasis due to C. albicans to study the patterns of fluconazole susceptibility of the isolates and the characteristics of the patients and to confirm the correlation between fluconazole susceptibility of isolates and therapeutic outcome. Sixty-one isolates were considered susceptible to fluconazole (MICs, < or = 0.5 microg/mL), 33 were intermediate (MICs, 1.0-8.0 microg/mL), and 25 were resistant (MICs, > or = 16.0 microg/mL). Patients infected with resistant strains had significantly lower CD4+ cell counts and a less recent AIDS diagnosis than patients infected with intermediate or susceptible strains. Previous fluconazole therapy and prophylaxis were significantly more frequent for patients infected with resistant and intermediate strains (P < .001). Decreased susceptibility to ketoconazole and itraconazole was observed in resistant and intermediate strains. Fluconazole treatment was ineffective for patients infected with resistant isolates; however, high doses of ketoconazole or itraconazole were successful for nine (81%) of them. Different patterns of fluconazole susceptibility among C. albicans strains are correlated with patients' characteristics and with therapeutic outcomes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9114134     DOI: 10.1093/clinids/24.2.124

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

Review 1.  Fungal resistance.

Authors:  H Bernhardt; K Zimmermann; M Knoke
Journal:  Infection       Date:  1999       Impact factor: 3.553

2.  Data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing.

Authors:  Isabel Cuesta; Concha Bielza; Pedro Larrañaga; Manuel Cuenca-Estrella; Fernando Laguna; Dolors Rodriguez-Pardo; Benito Almirante; Albert Pahissa; Juan L Rodríguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

3.  Evaluation of the fungitest kit by using strains from human immunodeficiency virus-infected patients: study of azole drug susceptibility.

Authors:  F Witthuhn; D Toubas; I Béguinot; D Aubert; C Rouger; G Remy; J M Pinon
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 4.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

5.  Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.

Authors:  Eduardo G Arathoon; Eduardo Gotuzzo; L Miguel Noriega; Rayanne S Berman; Mark J DiNubile; Carole A Sable
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 6.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Authors:  B D Alexander; J R Perfect
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

7.  Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.

Authors:  Juan L Rodríguez-Tudela; Benito Almirante; Dolors Rodríguez-Pardo; Fernando Laguna; J Peter Donnelly; Johan W Mouton; Albert Pahissa; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

Review 8.  Candida glabrata Biofilms: How Far Have We Come?

Authors:  Célia F Rodrigues; Maria Elisa Rodrigues; Sónia Silva; Mariana Henriques
Journal:  J Fungi (Basel)       Date:  2017-03-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.